Antitumor activity and cross-resistance of a novel podophyllotoxin analog, NK611, to human small-cell lung cancer cell lines

N. Takigawa, H. Ueoka, Katsuyuki Kiura, Masahiro Tabata, T. Shibayama, A. Bessho, K. Aoe, H. Fujioka, T. Ohnoshi, M. Harada

Research output: Contribution to journalArticle

Abstract

We compared the antitumor activity of etoposide, teniposide, and a novel podophyllotoxin analog, NK611, with the MTT assay using a human small-cell lung cancer cell line, SBC-3, with 1-hour drug exposure. The ratio of the area under the curve (AUC) to the 50% inhibitory concentration (IC50) of each drug was used as an index of antitumor activity. The AUC/IC50 ratio of NK611 was 13.6, which was comparable with etoposide (13.5), but inferior to teniposide (90.1). The degree of cross-resistance of teniposide and NK611 to etoposide was investigated using an etoposide-resistant subline, SBC-3/ETP, which was 17.4-fold more resistant to etoposide than the parent cell line, SBC-3. The SBC-3/ETP cell line was 7.64-fold more resistant to teniposide than the SBC-3 cell line. Nevertheless, the resistant cell line was only 2.64-fold more resistant to NK611 than the parent cell line. These observations suggest that NK611 may be beneficial in the treatment of etoposide-resistant small cell lung cancer.

Original languageEnglish
Pages (from-to)49-54
Number of pages6
JournalJapanese Journal of Lung Cancer
Volume35
Issue number1
Publication statusPublished - 1995

Fingerprint

Podophyllotoxin
Small Cell Lung Carcinoma
Etoposide
Teniposide
Cell Line
Inhibitory Concentration 50
Area Under Curve
Pharmaceutical Preparations
NK 611

Keywords

  • drug resistance
  • etoposide
  • lung cancer cell line
  • NK611
  • teniposide

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Antitumor activity and cross-resistance of a novel podophyllotoxin analog, NK611, to human small-cell lung cancer cell lines. / Takigawa, N.; Ueoka, H.; Kiura, Katsuyuki; Tabata, Masahiro; Shibayama, T.; Bessho, A.; Aoe, K.; Fujioka, H.; Ohnoshi, T.; Harada, M.

In: Japanese Journal of Lung Cancer, Vol. 35, No. 1, 1995, p. 49-54.

Research output: Contribution to journalArticle

Takigawa, N, Ueoka, H, Kiura, K, Tabata, M, Shibayama, T, Bessho, A, Aoe, K, Fujioka, H, Ohnoshi, T & Harada, M 1995, 'Antitumor activity and cross-resistance of a novel podophyllotoxin analog, NK611, to human small-cell lung cancer cell lines', Japanese Journal of Lung Cancer, vol. 35, no. 1, pp. 49-54.
Takigawa, N. ; Ueoka, H. ; Kiura, Katsuyuki ; Tabata, Masahiro ; Shibayama, T. ; Bessho, A. ; Aoe, K. ; Fujioka, H. ; Ohnoshi, T. ; Harada, M. / Antitumor activity and cross-resistance of a novel podophyllotoxin analog, NK611, to human small-cell lung cancer cell lines. In: Japanese Journal of Lung Cancer. 1995 ; Vol. 35, No. 1. pp. 49-54.
@article{ece66fba758e43b483b1207a1702aa01,
title = "Antitumor activity and cross-resistance of a novel podophyllotoxin analog, NK611, to human small-cell lung cancer cell lines",
abstract = "We compared the antitumor activity of etoposide, teniposide, and a novel podophyllotoxin analog, NK611, with the MTT assay using a human small-cell lung cancer cell line, SBC-3, with 1-hour drug exposure. The ratio of the area under the curve (AUC) to the 50{\%} inhibitory concentration (IC50) of each drug was used as an index of antitumor activity. The AUC/IC50 ratio of NK611 was 13.6, which was comparable with etoposide (13.5), but inferior to teniposide (90.1). The degree of cross-resistance of teniposide and NK611 to etoposide was investigated using an etoposide-resistant subline, SBC-3/ETP, which was 17.4-fold more resistant to etoposide than the parent cell line, SBC-3. The SBC-3/ETP cell line was 7.64-fold more resistant to teniposide than the SBC-3 cell line. Nevertheless, the resistant cell line was only 2.64-fold more resistant to NK611 than the parent cell line. These observations suggest that NK611 may be beneficial in the treatment of etoposide-resistant small cell lung cancer.",
keywords = "drug resistance, etoposide, lung cancer cell line, NK611, teniposide",
author = "N. Takigawa and H. Ueoka and Katsuyuki Kiura and Masahiro Tabata and T. Shibayama and A. Bessho and K. Aoe and H. Fujioka and T. Ohnoshi and M. Harada",
year = "1995",
language = "English",
volume = "35",
pages = "49--54",
journal = "Japanese Journal of Lung Cancer",
issn = "0386-9628",
publisher = "Japan Lung Cancer Society",
number = "1",

}

TY - JOUR

T1 - Antitumor activity and cross-resistance of a novel podophyllotoxin analog, NK611, to human small-cell lung cancer cell lines

AU - Takigawa, N.

AU - Ueoka, H.

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Shibayama, T.

AU - Bessho, A.

AU - Aoe, K.

AU - Fujioka, H.

AU - Ohnoshi, T.

AU - Harada, M.

PY - 1995

Y1 - 1995

N2 - We compared the antitumor activity of etoposide, teniposide, and a novel podophyllotoxin analog, NK611, with the MTT assay using a human small-cell lung cancer cell line, SBC-3, with 1-hour drug exposure. The ratio of the area under the curve (AUC) to the 50% inhibitory concentration (IC50) of each drug was used as an index of antitumor activity. The AUC/IC50 ratio of NK611 was 13.6, which was comparable with etoposide (13.5), but inferior to teniposide (90.1). The degree of cross-resistance of teniposide and NK611 to etoposide was investigated using an etoposide-resistant subline, SBC-3/ETP, which was 17.4-fold more resistant to etoposide than the parent cell line, SBC-3. The SBC-3/ETP cell line was 7.64-fold more resistant to teniposide than the SBC-3 cell line. Nevertheless, the resistant cell line was only 2.64-fold more resistant to NK611 than the parent cell line. These observations suggest that NK611 may be beneficial in the treatment of etoposide-resistant small cell lung cancer.

AB - We compared the antitumor activity of etoposide, teniposide, and a novel podophyllotoxin analog, NK611, with the MTT assay using a human small-cell lung cancer cell line, SBC-3, with 1-hour drug exposure. The ratio of the area under the curve (AUC) to the 50% inhibitory concentration (IC50) of each drug was used as an index of antitumor activity. The AUC/IC50 ratio of NK611 was 13.6, which was comparable with etoposide (13.5), but inferior to teniposide (90.1). The degree of cross-resistance of teniposide and NK611 to etoposide was investigated using an etoposide-resistant subline, SBC-3/ETP, which was 17.4-fold more resistant to etoposide than the parent cell line, SBC-3. The SBC-3/ETP cell line was 7.64-fold more resistant to teniposide than the SBC-3 cell line. Nevertheless, the resistant cell line was only 2.64-fold more resistant to NK611 than the parent cell line. These observations suggest that NK611 may be beneficial in the treatment of etoposide-resistant small cell lung cancer.

KW - drug resistance

KW - etoposide

KW - lung cancer cell line

KW - NK611

KW - teniposide

UR - http://www.scopus.com/inward/record.url?scp=0028948228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028948228&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028948228

VL - 35

SP - 49

EP - 54

JO - Japanese Journal of Lung Cancer

JF - Japanese Journal of Lung Cancer

SN - 0386-9628

IS - 1

ER -